Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

295994

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans to launch a Phase 2 trial in early 2022 to test fezagepras in people with IPF. While Liminal, formerly known as Prometic Life Sciences, did not fully disclose the…

You must be logged in to read/download the full post.